List view / Grid view
30 September 2014 | By Roche
Roche and InterMune, Inc. announced that Roche’s wholly owned subsidiary Klee Acquisition Corporation has accepted for payment all shares validly tendered pursuant to its tender offer for all outstanding shares of common stock of InterMune, Inc. at USD 74.00 per share in cash...
30 September 2014 | By Roche
Roche announced final survival results from the Phase III CLEOPATRA study, which showed that adding Perjeta (pertuzumab) to Herceptin (trastuzumab) and docetaxel chemotherapy extended the lives of people with previously untreated HER2-positive metastatic breast cancer...
30 September 2014 | By kdm communications
Cresset, innovative provider of computational chemistry software and services, has provided a donation to Novartis Institutes for Biomedical Research’s (NIBR) in support of their TExts to Sub-Saharan Africa (TESSA) project...
30 September 2014 | By Frost & Sullivan
Distributors are expected to deploy a multi-sector, multi-brand strategy to broaden their business, says Frost & Sullivan...
29 September 2014 | By AstraZeneca
AstraZeneca will present new data from its pipeline of investigational cancer medicines over the next three days at the European Society of Medical Oncology (ESMO) 2014 Congress in Madrid...
29 September 2014 | By Roche
Roche has announced the first combination data of its investigational cancer immunotherapy MPDL3280A and Avastin in untreated patients with mRCC...
29 September 2014 | By kdm communications
Digitron – an Elektron Technology brand – has announced new additions to its extensive range of robust hand-held digital thermometers...
29 September 2014 | By Janssen
Janssen-Cilag International NV announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency has granted a Positive Opinion recommending REZOLSTA™...
29 September 2014 | By Sigmoid Pharma Limited
SIGMOID PHARMA LIMITED and Pendopharm have entered into agreements concerning a licence for exclusive rights to commercialise CyCol® in the Canadian market and an equity investment in SIGMOID...
29 September 2014 | By Kymab
Following a US$40 million Series B investment from The Wellcome Trust and the Bill & Melinda Gates Foundation...
29 September 2014 | By Abbott
Abbott has acquired control of CFR Pharmaceuticals, more than doubling its Latin American branded generics pharmaceutical presence and further expanding the company's presence in fast-growing markets...
29 September 2014 | By Gilead
Gilead Sciences, Inc. announced that the Committee for Medicinal Products for Human Use has adopted a positive opinion on the company’s Marketing Authorization Application for Harvoni®...
29 September 2014 | By Boehringer Ingelheim
Boehringer Ingelheim announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency has issued a positive opinion for the approval of nintedanib*...
29 September 2014 | By Roche
Roche announced positive data from the coBRIM Phase III study...
29 September 2014 | By Bristol-Myers Squibb Company
Bristol-Myers Squibb Company announced positive results from CheckMate -037, a Phase 3 randomized, controlled open-label study of Opdivo (nivolumab), an investigational PD-1 immune checkpoint inhibitor, versus investigator’s choice chemotherapy (ICC) in patients with advanced melanoma who were previously treated with Yervoy (ipilimumab)...
